![]() |
![]() |
| • |
HAMR™ Furnace Capacity Validated Above 200 tpa: HAMR™ titanium powder production continued to ramp on a
24/7 schedule, completing 1.6 tons of back-to-back deoxygenation runs in 63 hours and validated furnace capacity above the 200 tpa target annualized run-rate.
|
| • |
Aerospace-Grade Quality: HAMR™ powder consistently met or exceeded Grade 5 titanium quality specifications,
confirming HAMR™ as a commercially proven process for primary titanium metal production.
|
| • |
Production & Inventory Volumes: Produced 8.7 tons of titanium HAMR™ powder during the quarter (June
quarter: 1.4 tons), closing the period with 19 tons of finished titanium powder inventory and 207 tons of titanium scrap feedstock.
|
| • |
Near-term Commercial Programs: With titanium powder capacity validated and inventory established,
downstream manufacturing and near-term commercial program execution are now the operational priorities, supported by increased customer qualification.
|
| • |
Titanium Fastener Manufacturing: Optimized the 300-ton, six-axis SACMI powder metallurgy press tooling and
pressing parameters for a large range of titanium fastener geometries across defense and commercial applications.
|
| • |
Domestic Billet & Bar Products: Dedicated wet-bag cold isostatic press (CIP) production to large
titanium billet and bar production for internal fastener manufacturing and as a domestic alternative to conventional titanium bar and wire mill products.
|
| • |
Sintering Bottleneck Relieved: Commissioned the first of two additional Elnik HSPT™ sintering furnaces,
with the second furnace now installed and scheduled for commissioning in the December quarter, removing a key downstream manufacturing constraint and increasing finished titanium product output.
|
| • |
In-House Virginia Fastener Manufacturing: Expanded in-house finish machining and thread-rolling
capabilities. Fastener production now runs largely in-house in Virginia to meet current needs, spanning uniaxial pressing, HSPT™ sintering, THRM™ heat treatment, finish machining, and thread rolling, with centerless grinding to be brought
in-house under Task Order 2. Produced 1,500 fasteners with further production now scaling for U.S. Army and commercial programs.
|
| • |
Multi-Sector Component Development: Advanced additive manufacturing and powder-to-product programs across
defense, aerospace, consumer electronics, and industrial applications, alongside advancing titanium plate and large-format titanium component manufacturing.
|
| • |
Breakthrough Continuous Validation: Validated the next-generation GenX™ continuous HAMR™ production
platform, processing over 500 kg of titanium powder across four continuous runs (41 hours), with 100% of valid samples meeting ASTM oxygen specifications.
|
| • |
Step-Change in Unit Economics: Compared to batch HAMR™ on a like-for-like run-time basis, GenX™ delivered
6x higher throughput while reducing power consumption by >75%, magnesium usage by >45%, and hydrogen consumption by >60% per kilogram of titanium powder.
|
| • |
100 tpa Titanium Powder Production Capacity: Validated the current GenX™ platform at an equivalent run-rate
of ~100 tpa; engineering is underway to integrate the full production line and bring this incremental capacity online.
|
|
Virginia
|
Tennessee
|
Utah
|
|
|
1092 Confroy Drive
South Boston, VA 24592
|
279 West Main Street
Camden, TN 38320
|
1782 W 2300 S
West Valley City, UT 84119
|
|
|
IperionX Limited ABN 84 618 935 372
|
|||
| • |
U.S. Navy + Carver Pump: Completed manufacturing of all titanium components under the Carver Pump purchase
order; components are now undergoing final customer testing to support commercial-scale orders for U.S. Navy pump contractors.
|
| • |
U.S. Army + American Rheinmetall Vehicles: Advanced manufacturing of large format titanium track pins under
the U.S. Army prototype order, leveraging new Elnik HSPT™ sintering capacity to support larger follow-on production orders across U.S. Army ground combat platforms.
|
| • |
U.S. Army GVSC Titanium Fasteners: Secured a follow-on purchase order from the U.S. Army Ground Vehicle
Systems Center (GVSC) for titanium fasteners for the Joint Light Tactical Vehicle (JLTV) and trailer. Independent test work validated that IperionX titanium fasteners exceed SAE Grade 8 steel torque-to-yield performance.
|
| • |
Targeting Mill Markets: U.S. titanium mill product supply remains constrained, underscored by the sectors’
record order backlog and near 20-month lead times for premium titanium products. IperionX’s CIP billet and bar program directly targets this supply gap.
|
| • |
Commercial Pipeline Maturation: Advanced the customer pipeline from material validation to component
testing, prototype orders, and funded scale-up, targeting recurring, higher-value revenue across four core verticals:
|
| o |
Titanium mill products for established mill and aerospace customers;
|
| o |
Aerospace defense primes, with an emphasis on missile systems;
|
| o |
Ground and naval defense contractors, building on active U.S. Army and U.S. Navy programs; and
|
| o |
Spherical titanium powder for consumer goods and electronics.
|
| • |
Tier-1 Project Economics: The U.S. Government-supported Titan Definitive Feasibility Study (DFS),
completed in June, demonstrated an after-tax NPV8 of US$813 million, an after-tax IRR of 39.4%, a 3.6-year payback period, and US$1.9 billion in cumulative after-tax free cash flow over an initial 14-year mine life.
|
| • |
Strategic Atlas Acquisition Closed: Completed the US$3 million acquisition of the adjacent Atlas critical
mineral and infrastructure assets on July 1, 2026 (following the June agreement).
|
| • |
Immediate Infrastructure & Resource Synergies: Atlas adds ~70 acres of at-surface stockpiles, 180
acres of pre-stripped critical mineral mineralization, and established power, water, natural gas, and rail infrastructure. The full integrated Atlas-Titan economic assessment is underway.
|
| • |
US$18.5M Task Order 2 Award: The U.S. Army awarded Task Order 2 under IperionX’s US$99 million SBIR Phase
III IDIQ contract, with an US$18.5 million base value (US$11.5 million initially funded) and scoped options bringing the total potential value to US$25.4 million.
|
| • |
Remaining Contract Ceiling: Task Order 2 funding for continuous HSPT™ and dehydride furnaces alongside
in-house fastener finishing in Virginia. Combined awards under Task Orders 1 and 2 total ~US$19.8 million, leaving US$79.2 million available under the existing US$99 million contract ceiling.
|
| • |
U.S. titanium Supply Chain Funding Proposal Submitted: Submitted a formal proposal under Defense
Industrial Base Consortium solicitation RPP-CM-26-02 (Domestic Processing Capabilities of Critical Minerals), which designates titanium, including titanium sponge substitutes, as a priority defense material.
|
| • |
1,400 tpa Expansion: Continued execution of the 1,400 tpa titanium capacity expansion under the fully
obligated US$47.1 million IBAS award, the US$12.7 million DPA Title III award, and ~290 metric tons of no-cost U.S. Government titanium scrap transfers.
|
| • |
Strong Balance Sheet & Liquidity: Closed the quarter with US$63.0 million in cash (June 30, 2026:
US$35.2 million), supplemented by US$33.7 million in remaining obligated, reimbursable U.S. Government funding (including US$0.5 million in incurred expenditure pending reimbursement for IBAS and another $0.3m pending reimbursement from SBIR)
- providing approximately US$96.7 million in total available liquidity. Net operating cash outflow was US$12.6 million, deployed across the Virginia production ramp, product qualification, and GenX™ R&D.
|
| • |
US$50M U.S. Public Offering: Priced an underwritten U.S. public offering on July 7, 2026, issuing
2,275,000 ADSs at US$21.98 per ADS for gross proceeds of ~US$50.0 million (net proceeds of ~US$46.1 million).
|
| • |
Director On-Market Purchases: Directors acquired ~US$1.9 million of IperionX shares via on-market
purchases in July, underscoring strong board alignment with shareholders.
|
| • |
Proposed U.S. Redomiciliation: Announced plans on August 3, 2026, to redomicile to a Texas parent company
with common stock listed directly on Nasdaq (replacing the current ADS structure), subject to shareholder, court, and regulatory approvals.
|
| • |
Board Strengthened: Appointed Michael J. Loparco as an Independent Non-Executive Director on August 3,
2026, bringing over 25 years of global advanced manufacturing and supply-chain leadership at Jabil and Symbotic.
|
|
IperionX’s mission is to reshore a 100% domestic, low-cost and uninterruptible titanium supply chain, from critical minerals and recycled feedstock through to finished
titanium components. IperionX operates across two business units:
1. Titanium metal operations – proprietary titanium manufacturing in Virginia, supported by R&D facilities in Virginia and Utah; and
2. Critical mineral operations – advancing the integrated Atlas-Titan platform in Tennessee as a domestic source of titanium, heavy rare earth and zircon critical minerals.
|
![]() Figure 1: IperionX operational locations
|


|
Quarter at a glance
|
September 2026 quarter
|
|||
|
Titanium powder produced
|
8.7 tons (June quarter: 1.4 tons)
|
|||
|
Titanium powder inventory at quarter end
|
19 tons
|
|||
|
Titanium scrap feedstock inventory
|
207 tons
|
|||
|
HAMR™ furnace capacity demonstrated
|
1.6 tons in 63 hours, above the 200 tpa nameplate capacity
|
|||
|
Powder process steps rated at ≥200 tpa run-rate
|
All major steps except powder drying (expected December quarter)
|
|||
|
GenX™ continuous HAMR™ validation
|
Validated at approximately 100 tpa equivalent rate; 6x throughput, >75% lower power, >45% less magnesium, >60% less hydrogen (vs. batch HAMR™)
|
|||
|
New U.S. Government funding
|
US$18.5 million SBIR Phase III Task Order 2 (US$11.5 million funded)
|
|||
|
Cash at September 30, 2026
|
US$63.0 million (June 30, 2026: US$35.2 million)
|
|||
|
Net cash used in operating activities
|
US$12.6 million
|
|||
|
Remaining obligated reimbursable U.S. Government funding
|
US$33.7 million
|



| • |
Engineered Products include customer-specific components such as titanium fasteners, impellers, track pins and near-net-shape
parts. Upfront prototyping and qualification will support near-term, high margin repeat orders once qualified.
|
| • |
Mill Products include titanium plate, sheet and bar, providing a pathway to ballistic-grade plate and large-format military
components in a large, strategic sector where domestic supply and lead time are increasingly critical.
|
| • |
Titanium Powders remain strategically important for additive manufacturing. IperionX prioritizes conversion into higher-value
products while retaining flexibility to scale direct powder sales with customer demand.
|

|
U.S. Government program
|
Award date
|
Amount
|
Capacity / Capability
|
|
|
Defense Production Act Title III
|
Oct. 31, 2023
|
US$12.7 million
|
200 tpa
|
|
|
Industrial Base Analysis & Sustainment
|
Feb. 16, 2025
|
US$47.1 million
|
+1,200 tpa
|
|
|
SBIR Phase III – Task Order 2
|
Aug. 31, 2026
|
US$18.5 million
(US$11.5 million obligated)
|
HSPT™, HDH & fastener finishing
|
|
Operating measure
|
Measured GenX™ result
|
Comparison basis (batch HAMR™)
|
||
|
Magnesium consumption
|
>45% lower
|
Per kg of titanium powder
|
||
|
Hydrogen consumption
|
>60% lower
|
Per kg of titanium powder
|
||
|
Power consumption
|
>75% lower
|
Per kg of titanium powder
|
||
|
Processing throughput
|
6 times
|
Like-for-like run time
|

|
Program
|
Award
|
Obligated
|
Reimbursed
to date
|
Remaining
reimbursable
|
Incurred, not
yet reimbursed
|
|
|
DPA Title III
|
$12.7m
|
$12.7m
|
$12.7m
|
-
|
-
|
|
|
IBAS
|
$47.1m
|
$47.1m
|
$13.4m
|
$33.7m
|
$0.5m
|
|
|
Total program
|
$59.8m
|
$59.8m
|
$26.1m
|
$33.7m
|
$0.5m
|
|
Contract
|
Contract ceiling
|
Task orders received
|
Contract balance
|
|||
|
SBIR Phase III
|
Up to
|
$99.0m
|
$19.8m
|
Up to
|
$79.2m
|
|
|
Equity
|
US$m
|
Comment
|
||
|
U.S. public offering (net)
|
46.1
|
Equity raise net of expenses
|
||
|
Stock options
|
0.1
|
Director’s exercise of stock options
|
||
|
Subtotal
|
46.2
|
|
Core operations
|
US$m
|
Comment
|
||
|
Staff costs
|
(5.1)
|
Salaries, wages and benefits
|
||
|
G&A
|
(3.3)
|
Overhead and corporate operating costs
|
||
|
Exploration
|
(0.5)
|
Drilling and other expenditures
|
||
|
R&D (operations)
|
(2.1)
|
Activities relating to operations including new product development
|
||
|
R&D (GenXTM)
|
(0.3)
|
Development and scale up of continuous HAMRTM (GenXTM)
|
||
|
Materials
|
(0.9)
|
Purchase of materials related to production
|
||
|
Consumables
|
(1.0)
|
Purchase of materials related to prototyping or R&D activities
|
||
|
Capex (ex. DoW, GenXTM and Atlas)
|
(3.1)
|
Phase 1 (200 tpa) development
|
||
|
Subtotal
|
(16.3)
|
|
U.S. Government activities
|
US$m
|
Comment
|
||
|
DoW – 1,400 tpa spend
|
(2.1)
|
Capex for scale up to 1,400 tpa
|
||
|
DoW – 1,400 tpa reimbursed
|
3.4
|
Reimbursement for capex for scale up to 1,400 tpa
|
||
|
Subtotal
|
1.3
|
|
Other material / non-run-rate items
|
US$m
|
Comment
|
||
|
Atlas acquisition
|
(2.9)
|
Closing payment $3 million Atlas acquisition
|
||
|
Redomiciliation
|
(0.1)
|
|||
|
SOX and ERP implementation
|
(0.4)
|
Compliance with Sarbanes-Oxley and ERP implementation
|
||
|
Subtotal
|
(3.4)
|

|
Activity
|
US$000
|
||
|
Mining and engineering consultants
|
(322)
|
||
|
Geological consultants
|
(54)
|
||
|
Drilling
|
(12)
|
||
|
Assaying
|
(27)
|
||
|
Permitting
|
(5)
|
||
|
Field supplies, equipment rental, vehicles, travel and deposit refunds
|
(85)
|
||
|
Total as reported in Appendix 5B
|
(505)
|
|
Forward Looking Statements
Information included in this release constitutes forward-looking statements. Often, but not always, forward
looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “continue”, and “guidance”, or other similar words and may include, without
limitation, statements regarding plans, strategies and objectives of management, anticipated production or construction commencement dates and expected costs or production outputs.
Forward looking statements inherently involve known and unknown risks, uncertainties and other factors that may
cause the Company’s actual results, performance, and achievements to differ materially from any forecast future results, performance, or achievements. Relevant factors may include, but are not limited to, changes in commodity prices, foreign
exchange fluctuations and general economic conditions, increased costs and demand for production inputs, the speculative nature of exploration and project development, including the risks of obtaining necessary licenses and permits and
diminishing quantities or grades of mineralization, the Company’s ability to comply with the relevant contractual terms to access the technologies, commercially scale its closed-loop titanium production processes, or protect its intellectual
property rights, political and social risks, changes to the regulatory framework within which the Company operates or may in the future operate, environmental conditions including extreme weather conditions, recruitment and retention of
personnel, industrial relations issues and litigation.
Forward looking statements are based on the Company and its management’s good faith assumptions relating to the
financial, market, regulatory and other relevant environments that will exist and affect the Company’s business and operations in the future. The Company does not give any assurance that the assumptions on which forward looking statements are
based will prove to be correct, or that the Company’s business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company’s control.
Although the Company attempts and has attempted to identify factors that would cause actual actions, events or results to differ materially from
those disclosed in forward looking statements, there may be other factors that could cause actual results, performance, achievements, or events not to be as anticipated, estimated or intended, and many events are beyond the reasonable control
of the Company. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward looking statements in these materials speak only at the date of issue. Subject to any continuing obligations under applicable
law or any relevant stock exchange listing rules, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or
circumstances on which any such statement is based.
Compliance Statement
This announcement contains information relating to a Mineral Resource Estimate and an Ore Reserve Estimate for the Titan deposit (where the Mineral
Resource Estimate was prepared by Mr. John Eckman, a Competent Person, and the Ore Reserve Estimate was prepared by Mr. Justin Douthat, also a Competent Person) extracted from an ASX market announcement titled “IperionX Titan DFS Confirms
High-Return U.S. Rare Earths and Critical Minerals Project” and published on the ASX platform (www.asx.com.au) on 4 June 2026. The Company confirms that it is not aware of any new information or data that materially affects the information
included in the original market announcement and that all material assumptions and technical parameters underpinning the estimates in the release of 4 June 2026 continue to apply and have not materially changed. The Company confirms that the
form and context in which the Competent Persons' findings are presented have not been materially modified from the original market announcement.
This announcement contains exploration results relating to the Atlas deposit extracted from an ASX market announcement titled “Acquisition Delivers
High Value Critical Minerals” and published on the ASX platform (www.asx.com.au) on 2 July 2026. The Company confirms that it is not aware of any new information or data that materially affects the information included in the original market
announcement. The Company confirms that the form and context in which the Competent Persons' findings are presented have not been materially modified from the original market announcement. The Competent Person was Mr Adam Karst.
This announcement contains production target and forecast financial information extracted from an ASX announcement titled “IperionX Titan DFS
Confirms High-Return US Rare Earths and Critical Minerals Project” and published on the ASX platform (www.asx.com.au) on 4 June 2026. The Company confirms that all material assumptions underpinning the production target and forecast financial
information disclosed in the ASX announcement dated June 4, 2026 continue to apply and have not materially changed.
|
||
|
Name of entity
|
||||
|
IperionX Limited
|
||||
|
ABN
|
Quarter ended (“current quarter”)
|
|||
|
84618935372
|
September 30, 2026
|
| Consolidated statement of cash flows |
Current
quarter
USD $’000
|
Year to date
(3 months)
USD $’000
|
|||
|
1
|
Cash flows from operating activities
|
||||
|
1.1
|
Receipts from customers
|
46
|
46
|
||
|
1.2
|
Payments for
|
||||
|
(a) exploration & evaluation
|
(505)
|
(505)
|
|||
|
(b) development
|
—
|
—
|
|||
|
(c) production
|
(905)
|
(905)
|
|||
|
(d) staff costs
|
(5,094)
|
(5,094)
|
|||
|
(e) administration and corporate costs
|
(3,225)
|
(3,225)
|
|||
|
1.3
|
Dividends received
|
—
|
—
|
||
|
1.4
|
Interest received
|
507
|
507
|
||
|
1.5
|
Interest and other costs of finance paid
|
(80)
|
(80)
|
||
|
1.6
|
Income taxes paid
|
—
|
—
|
||
|
1.7
|
Government grants and tax incentives
|
—
|
—
|
||
|
1.8
|
Other (provide details if material):
|
||||
|
(a) research & development
|
(3,139)
|
(3,139)
|
|||
|
(b) business development
|
(222)
|
(222)
|
|||
|
1.9
|
Net cash from / (used in) operating activities
|
(12,617)
|
(12,617)
|
||
|
2
|
Cash flows from investing activities
|
||||
|
2.1
|
Payments to acquire:
|
||||
|
(a) entities
|
—
|
—
|
|||
|
(b) tenements
|
(2,729)
|
(2,729)
|
|||
|
(c) property, plant and equipment
|
(4,825)
|
(4,825)
|
|||
|
(d) exploration & evaluation
|
—
|
—
|
|||
| Consolidated statement of cash flows |
Current
quarter
USD $’000
|
Year to date
(3 months)
USD $’000
|
|||
|
(e) investments
|
—
|
—
|
|||
|
(f) other non-current assets
|
—
|
—
|
|||
|
2.2
|
Proceeds from the disposal of:
|
||||
|
(a) entities
|
—
|
—
|
|||
|
(b) tenements
|
—
|
—
|
|||
|
(c) property, plant and equipment(1)
|
1,808
|
1,808
|
|||
|
(d) investments
|
—
|
—
|
|||
|
(e) other non-current assets
|
—
|
—
|
|||
|
2.3
|
Cash flows from loans to other entities
|
—
|
—
|
||
|
2.4
|
Dividends received
|
—
|
—
|
||
|
2.5
|
Other (provide details if material)
|
—
|
—
|
||
|
2.6
|
Net cash from / (used in) investing activities
(1) Relates to plant and equipment recorded on our balance sheet, the cost of which has subsequently been reimbursed by the U.S. Government. Consequently, there has been a "deemed disposal" of
these assets to transfer title to the U.S. Government. Title to all assets purchased by IperionX with funds from the U.S. Government vest with the U.S. government during the term of the Technology Investment Agreement. At the end of the
agreement, title may be transferred back to IperionX subject to certain conditions.
|
(5,746)
|
(5,746)
|
||
|
3
|
Cash flows from financing activities
|
||||
|
3.1
|
Proceeds from issues of equity securities (excluding convertible debt securities)
|
50,005
|
50,005
|
||
|
3.2
|
Proceeds from issue of convertible debt securities
|
—
|
—
|
||
|
3.3
|
Proceeds from exercise of options
|
64
|
64
|
||
|
3.4
|
Transaction costs related to issues of equity securities or convertible debt securities
|
(3,857)
|
(3,857)
|
||
|
3.5
|
Proceeds from borrowings
|
—
|
—
|
||
|
3.6
|
Repayment of borrowings
|
(271)
|
(271)
|
||
|
3.7
|
Transaction costs related to loans and borrowings
|
—
|
—
|
||
|
3.8
|
Dividends paid
|
—
|
—
|
||
|
3.9
|
Other (provide details if material)
|
||||
|
(a) principal portion of lease liabilities
|
(126)
|
(126)
|
|||
|
(b) cash for securities not issued
|
—
|
—
|
|||
|
3.10
|
Net cash from / (used in) financing activities
|
45,815
|
45,815
|
||
| Consolidated statement of cash flows |
Current
quarter
USD $’000
|
Year to date
(3 months)
USD $’000
|
|||
|
4
|
Net increase / (decrease) in cash and cash equivalents for the period
|
||||
|
4.1
|
Cash and cash equivalents at beginning of period
|
35,244
|
35,244
|
||
|
4.2
|
Net cash from / (used in) operating activities (item 1.9 above)
|
(12,617)
|
(12,617)
|
||
|
4.3
|
Net cash from / (used in) investing activities (item 2.6 above)
|
(5,746)
|
(5,746)
|
||
|
4.4
|
Net cash from / (used in) financing activities (item 3.10 above)
|
45,815
|
45,815
|
||
|
4.5
|
Effect of movement in exchange rates on cash held
|
322
|
322
|
||
|
4.6
|
Cash and cash equivalents at end of period
|
63,018
|
63,018
|
||
|
5
|
Reconciliation of cash and cash equivalents
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts
|
Current quarter
USD $’000
|
Previous quarter
USD $’000
|
||
|
5.1
|
Bank balances
|
59,994
|
29,080
|
||
|
5.2
|
Call deposits
|
3,024
|
6,164
|
||
|
5.3
|
Bank overdrafts
|
—
|
—
|
||
|
5.4
|
Other (provide details)
|
—
|
—
|
||
|
5.5
|
Cash and cash equivalents at end of quarter (should equal item 4.6 above)
|
63,018
|
35,244
|
|
6.
|
Payments to related parties of the entity and their associates
|
Current quarter
USD$’000
|
||
|
6.1
|
Aggregate amount of payments to related parties and their associates included item 1
|
315
|
||
|
6.2
|
Aggregate amount of payments to related parties and their associates included item 2
|
—
|
||
|
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation
|
||||
|
7
|
Financing facilities
Note: the term “facility’ includes all forms of financing arrangements available to the entity.
Add notes as necessary for an understanding of the sources of finance available to the entity.
|
Total facility
amount at
quarter end
USD $’000
|
Amount
drawn at
quarter end
USD $’000
|
||
|
7.1
|
Loan facilities
|
—
|
—
|
||
|
7.2
|
Credit standby arrangements
|
—
|
—
|
||
|
7.3
|
Other (please specify)
|
—
|
—
|
||
|
7.4
|
Total financing facilities
|
—
|
—
|
||
|
7.5
|
Unused financing facilities available at quarter end
|
—
|
|||
|
7.6
|
Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.
|
||||
| Not Applicable | |||||
|
8
|
Estimated cash available for future operating activities
|
USD $’000
|
||
|
8.1
|
Net cash from / (used in) operating activities (item 1.9)
|
(12,617)
|
||
|
8.2
|
(Payments for exploration & evaluation classified as investment activities) (item 2.1(d))
|
—
|
||
|
8.3
|
Total relevant outgoings (item 8.1 + item 8.2)
|
(12,617)
|
||
|
8.4
|
Cash and cash equivalents at quarter end (item 4.6)
|
63,018
|
||
|
8.5
|
Unused finance facilities available at quarter end (item 7.5)
|
—
|
||
|
8.6
|
Total available funding (item 8.4 + item 8.5)
|
63,018
|
||
|
8.7
|
Estimated quarters of funding available (item 8.6 divided by item 8.3)
|
5
|
|
8.8
|
If item 8.7 is less than 2 quarters, please provide answers to the following questions:
|
|||
|
8.8.1
|
Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?
|
|||
|
Not applicable.
|
||||
|
8.8.2
|
Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
|
|||
|
Not applicable.
|
||||
|
8.8.3
|
Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
|
|||
|
Not applicable.
|
||||
| Note: where item 8.7 is less than 2 quarters, all of questions 8.8.1, 8.8.2 and 8.8.3 above must be answered. | ||||
| 1 |
This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
|
| 2 |
This statement gives a true and fair view of the matters disclosed.
|
|
Date:
|
October 29, 2026
|
|
Authorized by:
|
Chief Financial Officer
|